Podcast appearances and mentions of don benson

In the late 1970s, there were only a small handful of commercial stations featuring jazz programming. But WQXI-FM ("94Q")-- a extremely successful Atlanta pop rock station--- added a 5-hour jazz show Sunday nights 7 to midnight, and generated double digit shares-  Sometimes 20+ shares Adults 25-54!  Here's the inside story from Don Benson, the PD who put it on, and from Fleetwood Gruver and Russ Davis, the first two hosts, who both went on to CD-101 in New York, one of the biggest jazz stations in the country. It's all here, in FoGRPod #19 from Friends of Georgia Radio. Dennis Winslow hosts.

Listen to a blog summary on a trending editorial published in Volume 14 of Oncotarget: “To be or not to be: the role of CD56 in multiple myeloma.” ___________________________________________________________ Multiple myeloma (MM) is a type of blood cancer that affects plasma cells in the bone marrow. These plasma cells, which are responsible for producing antibodies, become abnormal and begin to grow uncontrollably. This results in a buildup of abnormal cells in the bone marrow, leading to decreased production of healthy blood cells, bone damage and a host of other symptoms. MM is incredibly heterogenic, and this variability often leads to unsatisfactory long-term treatment outcomes in many patients with MM. Targets for new treatments and biomarkers of response are needed to improve patient outcomes. In a new editorial paper published in Oncotarget, researchers Francesca Cottini and Don Benson from The Ohio State University discuss a 2022 research paper they co-authored in which CD56 (or neuronal cell adhesion molecule; NCAM1) was thoroughly described as a biomarker and therapeutic target in multiple myeloma. On January 26, 2023, their editorial about this research paper was published in Oncotarget, entitled, “To be or not to be: the role of CD56 in multiple myeloma.” “Among others, CD56 is present at variable levels in approximately 70% of patients with multiple myeloma; however, very little is known about CD56 role in multiple myeloma.” (2022 Cottini et al.) Full blog - https://www.oncotarget.org/2023/02/02/the-importance-of-cd56-in-the-fight-against-multiple-myeloma/ DOI - https://doi.org/10.18632/oncotarget.28350 (PDF Download) Correspondence to - Francesca Cottini - Francesca.cottini@osumc.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28350 Keywords - myeloma, targeted therapies, CD56, signaling About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

I recently met singer, songwriter, luthier, and (believe it or not) game inventor Don Benson. He's a very interesting guy and I'm sure you'll enjoy meeting him too. You can listen to his music at: https://www.reverbnation.com/donbensonlatebloomer If you would like to talk with Don about building an instrument you can email him at donaldbenson@comcast.net --- Send in a voice message: https://anchor.fm/roger-humphrey/message Support this podcast: https://anchor.fm/roger-humphrey/support

Sedano & Kap start off the show with some Crosstalk with Mason & Ireland. There's some drama going on with Corporate Greg and some things he said about Mason & Ireland during Sedano & Kap yesterday… The guys discuss the drama with Corporate Greg and why they would never allow a trade back for him. Sedano explains why Saturday's UFC card is a just-watch. It's International Wing Day and the guys take calls from listeners about the best local wing places. Plus, Don Benson from the Benson family calls in to explain how he ended up hosting the Mandy's After Party. Learn more about your ad choices. Visit megaphone.fm/adchoices

Don Benson eventually ran the whole company as President and CEO of Lincoln Financial. Here's the behind-the-scenes story of his start as an intern for legendary programmer Scott Shannon and his arrival in Atlanta where he watched one of the most heavily promoted radio promotions of the 1970s fizzle because of a technical glitch. And, Dennis Winslow talks with Don about becoming PD of “The FM QXI,” and the birth of the iconic “94Q.”

A $10 million gift from the founder of Scottrade has created a unique and innovative new center at the James to fight multiple myeloma, a rare type of blood cancer. The goal “is to put drugs in veins, to give treatment to patients,” said Don Benson, MD, PhD. In this episode, Benson, one of the world's leading myeloma experts, describes the impact and creation of the Paula and Roger Riney Family Foundation Center for Advanced Research Excellence (Myeloma CARE). The $10 million gift will fund the development of five drugs in development by Benson and his James colleagues designed to treat myeloma. These drugs utilize immunotherapy and targeted (or precision) cancer treatment techniques “that will exploit the Achilles heel of myeloma cells, their vulnerability,” said Benson, the James Myeloma program director. “If one of the [five] projects is lagging, we'll kill it as soon as we can and focus on what's working. The goal is new treatments to patients as fast as possible.”

Join us as we celebrate two years of our podcast, and listen to excerpts from some of our favorite conversations: Bill Farrar, MD, on the history of The James and his friendship with the actual Dr. James; Doug Ulman on riding in his first Pelotonia; Don Benson, MD, PhD, and his patient, Matt Hare, on their special bond; Darryl Gray, MD, on how colonoscopies save lives, and the results of my very-own colonoscopy; and highlights from our Day in the Life of The James episode.

When Matt Hare was diagnosed with multiple myeloma, his life changed in ways he never could have imagined. He met a James physician, Don Benson, who would become part of his family, and he met the love of his life, Kate McGuinness, an extraordinary woman and caregiver. "I knew coming out of my (bone marrow transplant) that if I was able to achieve remission I was absolutely going to ask her to marry me," Matt says. In this episode, we learn about the great advances being made in the treatment of multiple myeloma, Matt's treatment plan, the outcome of his transplant and Kate's all-important answer to the big question. Which you may have already guessed.

Ep 13 Don Benson (1945 - 3 games ) interview by Rhett Bartlett. Don is 96yrs old at the time of this interview on 19 Sept 2016. He died 12 April 2019, aged 99 "I was working at a boiler maker at the time, we worked 6 days a week because it was through the war period. We worked Saturday morning and I got off at 10 o'clock and drove down (from Yallourn)to the footy (Richmond) and came home Saturday night." (copyright Rhett Bartlett)

You may have heard about checkpoint inhibitors - drugs that help take the breaks off the immune system to fight multiple myeloma. Learn more about how this new class of drugs is being used with all types of myeloma treatment and when they are best used from Dr. Don Benson, MD, PhD, an immunotherapy expert who has been actively researching this type of therapy for many years. 

Dr. Don Benson, MD, PhD of The James Cancer Center at Ohio State University is a multiple myeloma specialist with deep expertise in immunotherapy. He shares the growing and exciting world of immunotherapies in multiple myeloma - how they work and how they are opening up an exciting new set of opportunities for myeloma patients.

This week on mPatient Myeloma Radio, we welcome Dr. Don Benson of The James Comprehensive Cancer Center at Ohio State University back to discuss his research in nk cells, immunotherapy, and an upcoming PD-1 trial.

This week on HealthTree Podcast for Multiple Myeloma we welcome Dr. Don Benson of The James Comprehensive Cancer Center at Ohio State University back to discuss his research in nk cells, immunotherapy, and an upcoming PD-1 trial.

This week on mPatient Myeloma Radio, listen to the first in a two-part series with Dr. Benson as he gives us a primer in clinical trials. Because only 5% of myeloma patients participate in clinical trials, we want you to know all about them so you can understand why you would want to enroll, how they are staged, who funds them and what you can expect in outcomes.

This week on HealthTree Podcast for Multiple Myeloma, listen to the first in a two-part series with Dr. Benson as he gives us a primer in clinical trials. Because only 5% of myeloma patients participate in clinical trials, we want you to know all about them so you can understand why you would want to enroll, how they are staged, who funds them and what you can expect in outcomes.